UBS Group
RXRX icon

UBS Group’s Recursion Pharmaceuticals RXRX Stock Holding History

UBS Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,152
Closed -$132K – 10954
2026
Q1 		$132K Hold
43,152
– – ﹤0.01% 6858
2025
Q4 		$176K Sell
43,152
-144,948
-77% -$718K ﹤0.01% 6644
2025
Q3 		$918K Buy
+188,100
New +$988K ﹤0.01% 5647

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

UBS Group's RXRX Position: Q2 2026 in Review

UBS Group increased its Recursion Pharmaceuticals (RXRX) stake by 75% in Q2 2026, buying an estimated $12.8M and bringing the position to 8,947,102 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

UBS Group first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • UBS Group held 8,947,102 shares of Recursion Pharmaceuticals worth $32.8M as of Q2 2026.
  • UBS Group bought 3,845,865 Recursion Pharmaceuticals shares in Q2 2026, an estimated $12.8M.
  • Recursion Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2170 holding.
  • UBS Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.